Analysis: Shree Ganesh Rem

What does Shree Ganesh Rem do?

• Shree Ganesh Remedies Limited is a manufacturer of pharmaceutical intermediates and speciality chemicals with over two decades of operational expertise.
• The company specializes in complex chemistries, including halogenation, reduction, and Grignard reactions, serving global markets.
• Strategic acquisitions and infrastructure expansion (e.g., Ankleshwar, Dahej) have strengthened its position in high-value chemical synthesis.

• Pharmaceutical Intermediates: Focus on generic and off-patent molecules for global markets.
• Speciality & Fine Chemicals: Custom synthesis for agrochemicals, electronics, and semiconductor applications.
• CRAMS (Custom Research and Manufacturing Services): High-margin projects with European and Japanese clients.

Growth thesis

Shree Ganesh Remedies is a specialty chemicals and APIs company focused on CRAMS (Custom Research and Manufacturing Services) projects in agrochemicals, pharmaceuticals, and electronics. Key segments include CRAMS projects with European and Japanese customers, Block-7 expansion for niche molecules, and a pilot facility accelerating new product development. Growth will be driven by CRAMS commercial trials scaling post-approvals in FY27, Block-7 commercial production starting in Q2 FY27, and Block-8 reaching full capacity by FY26 end. Over 2-3 years, CRAMS diversification and margin normalization to 26-28% will underpin revenue growth, supported by Dahej plant construction (2-3 years) for high-volume projects. The key execution risk is regulatory and customer approval timelines for CRAMS projects, which could delay commercialization.

Why is Shree Ganesh Rem stock rising?

• Block-7 commercial production to commence in Q2 FY27, purpose-built for niche and CRAMS molecules
• CRAMS projects for European and Japanese customers moving from pilot trials to commercial trials; commercial scale start expected by later half of FY27
• New pilot facility fully operational; enabling faster new product development and quicker response to customer requirements
• FY27 expected to be a year where groundwork from FY26 translates into visible business outcomes; momentum to gradually build
• CRAMS business expected to begin gaining traction through FY27 as customer and regulatory approvals conclude

Research report

companyname: Shree Ganesh Remedies Limited ticker: 540737 sector: Pharmaceutical Intermediates and Specialty Chemicals Shree Ganesh Remedies Limited is a manufacturer of pharmaceutical intermediates and specialty chemicals. It has been operating for over 20 years, with manufacturing facilities in Ankleshwar and a strategic expansion site at Dahej. The company serves clients in over 20 countries across Europe, Japan, the US, and other regions. As of FY25, it employed 149 people. The company’s c...

Catalysts

capex, margin expansion

Growth guidance

No guidance